← All trials
NCT04464681
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 30, 2020
- Primary completion
- Oct 30, 2020
- Completion date
- Nov 30, 2020
- First posted
- Jul 9, 2020
- Last posted
- Jul 9, 2020
- Enrollment
- 9
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Kitasato UniversityLead sponsor
- Kitasato UniversityReponsible party - principal investigator
- Aetas Pharma Co., Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.